论文部分内容阅读
目的 :观察小剂量尿激酶治疗急性进展型脑梗死疗效。方法 :将 37例脑梗死患者分为治疗组 19例 ,对照组 18例。治疗组应用尿激酶 0 .5万U/kg静脉滴注 ,长龙通针剂 2 0ml+ 0 .90 %NS 2 0 0ml静滴至 3周末 ;对照组用长龙通针剂静滴。结果 :治疗组治疗前后相比 ,RD、RA、PV、Fg均有显著差异 ,P <0 .0 1;Hct、ESR有差异P <0 .0 5。治疗前后神经功能缺损积分差值为 :治疗组 14 .0 8,对照组 10 .0 9;两组有效率分别为 :治疗组 94.44% ,对照组 6 1.11%。结论 :采用尿激酶静滴治疗急性进展型脑梗死疗效显著 ,安全 ,值得临床推广应用。
Objective: To observe the efficacy of low-dose urokinase in the treatment of acute progressive cerebral infarction. Methods: Thirty-seven patients with cerebral infarction were divided into treatment group (n = 19) and control group (n = 18). Treatment group urokinase 0.5 million U / kg intravenous infusion, Changlong Tong injection 2 0ml +0. 90% NS 2 0 0ml intravenously until 3 weeks; control group with Changlong-injection intravenous infusion. Results: There were significant differences in RD, RA, PV, Fg between before and after treatment in the treatment group, P <0.01; Hct, ESR difference P <0. The difference of neurological deficit score before and after treatment was 14.08 in the treatment group and 10.90 in the control group. The effective rates of the two groups were 94.44% in the treatment group and 1.11% in the control group. Conclusion: The treatment of acute progressive cerebral infarction with intravenous infusion of urokinase has obvious curative effect and safety, which is worthy of clinical application.